Antifungal Agents: in Vitro Susceptibility Testing, Pharmacodynamics, and Prospects for Combination Therapy

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2004 Mar 12

PMID 15015031

Citations 20

Authors

A H Groll

H Kolve

Affiliations

Soon will be listed here.

Abstract

As invasive fungal infections in immunocompromised patients become increasingly important, the field of antifungal chemotherapy continues to evolve rapidly. New agents have entered the clinical arena, providing physicians with a variety of choices for treatment of most infections. Standardized methods for testing the in vitro susceptibility of fungi have become available, and concentration-effect relationships are increasingly explored. Finally, the availability of an entirely new class of antifungal agents is opening new opportunities for combination therapy of infections that are notoriously difficult to treat and carry a dismal prognosis. However, the ongoing progress in these key areas has also made antifungal chemotherapy considerably more complex and susceptible to misconceptions. Continuing efforts in the laboratory and well designed collaborative clinical trials are needed more than ever to turn opportunities into lasting benefit for patients at risk for or suffering from life-threatening invasive mycoses.

Citing Articles

RED light promotes flavonoid and phenolic accumulation in Cichorium spp. callus culture as anti-candida agent.

Abdelhamid S, Marzouk A, Asker M, El Shabrawi H Sci Rep. 2025; 15(1):2194.

PMID: 39820743 PMC: 11739635. DOI: 10.1038/s41598-024-85099-0.

Synergistic Interaction of Certain Essential Oils and Their Active Compounds with Fluconazole against Azole-resistant Strains of Cryptococcus neoformans.

Khan M Ann Afr Med. 2024; 23(3):391-399.

PMID: 39034564 PMC: 11364305. DOI: 10.4103/aam.aam_197_23.

Potential Original Drug for Aspergillosis: In Vitro and In Vivo Effects of 1-N,N-Dimethylamino-5-Isocyanonaphthalene (DIMICAN) on .

Szigeti Z, Talas L, Szeles A, Hargitai Z, Nagy Z, Nagy M J Fungi (Basel). 2022; 8(10).

PMID: 36294550 PMC: 9605569. DOI: 10.3390/jof8100985.

The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles.

Czyrski A, Resztak M, Swiderski P, Brylak J, Glowka F Pharmaceutics. 2021; 13(11).

PMID: 34834376 PMC: 8620887. DOI: 10.3390/pharmaceutics13111961.

Overview of Antifungal Drugs against Paracoccidioidomycosis: How Do We Start, Where Are We, and Where Are We Going?.

do Carmo Silva L, de Oliveira A, de Souza D, Barbosa K, Silva K, Carvalho Junior M J Fungi (Basel). 2020; 6(4).

PMID: 33228010 PMC: 7712482. DOI: 10.3390/jof6040300.

References

Anaissie E, Darouiche R, Abi-Said D, Uzun O, Mera J, Gentry L . Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996; 23(5):964-72. DOI: 10.1093/clinids/23.5.964. View

Rex J, Pappas P, Karchmer A, Sobel J, Edwards J, Hadley S . A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003; 36(10):1221-8. DOI: 10.1086/374850. View

Lewis R, Klepser M, Pfaller M . In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn Microbiol Infect Dis. 2000; 36(2):101-5. DOI: 10.1016/s0732-8893(99)00125-x. View

Bekersky I, Fielding R, Dressler D, Lee J, Buell D, Walsh T . Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother. 2002; 46(3):828-33. PMC: 127462. DOI: 10.1128/AAC.46.3.828-833.2002. View

Oakley K, Moore C, Denning D . In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother. 1998; 42(10):2726-30. PMC: 105927. DOI: 10.1128/AAC.42.10.2726. View

Vanden Bossche H, Dromer F, Improvisi I, Rex J, Sanglard D . Antifungal drug resistance in pathogenic fungi. Med Mycol. 1999; 36 Suppl 1:119-28. View

KURTZ M, Abruzzo G, Flattery A, Bartizal K, Marrinan J, Li W . Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun. 1996; 64(8):3244-51. PMC: 174214. DOI: 10.1128/iai.64.8.3244-3251.1996. View

Petraitiene R, Petraitis V, Groll A, Sein T, Schaufele R, Francesconi A . Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother. 2001; 46(1):12-23. PMC: 127008. DOI: 10.1128/AAC.46.1.12-23.2002. View

Hebart H, Loffler J, Meisner C, Serey F, Schmidt D, Bohme A . Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis. 2000; 181(5):1713-9. DOI: 10.1086/315435. View

10.

Groll A, Mickiene D, Petraitiene R, Petraitis V, Lyman C, Bacher J . Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother. 2001; 45(10):2845-55. PMC: 90741. DOI: 10.1128/AAC.45.10.2845-2855.2001. View

11.

Woods G . In vitro testing of antimicrobial agents. Infect Dis Clin North Am. 1995; 9(3):463-81. View

12.

HOFFMAN H, Ernst E, Klepser M . Novel triazole antifungal agents. Expert Opin Investig Drugs. 2000; 9(3):593-605. DOI: 10.1517/13543784.9.3.593. View

13.

Grant S, Clissold S . Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989; 37(3):310-44. DOI: 10.2165/00003495-198937030-00003. View

14.

Groll A, Piscitelli S, Walsh T . Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy. 2001; 21(8 Pt 2):133S-148S. DOI: 10.1592/phco.21.12.133s.34507. View

15.

Groll A, Walsh T . Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs. 2002; 10(8):1545-58. DOI: 10.1517/13543784.10.8.1545. View

16.

Caillot D, Casasnovas O, Bernard A, Couaillier J, Durand C, Cuisenier B . Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997; 15(1):139-47. DOI: 10.1200/JCO.1997.15.1.139. View

17.

Klepser M, Malone D, Lewis R, Ernst E, Pfaller M . Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrob Agents Chemother. 2000; 44(7):1917-20. PMC: 89985. DOI: 10.1128/AAC.44.7.1917-1920.2000. View

18.

Johnson E, Szekely A, Warnock D . In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1999; 42(6):741-5. DOI: 10.1093/jac/42.6.741. View

19.

Francis P, Walsh T . Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis. 1992; 15(6):1003-18. DOI: 10.1093/clind/15.6.1003. View

20.

Scalarone G, Mikami Y, Kurita N, Yazawa K, Miyaji M . The postantifungal effect of 5-fluorocytosine on Candida albicans. J Antimicrob Chemother. 1992; 29(2):129-36. DOI: 10.1093/jac/29.2.129. View